Objective-The purpose of this study was to examine the association between serum levels of osteoprotegerin (OPG) and receptor activator of nuclear factor-B ligand (RANKL) and future coronary artery disease (CAD) in apparently healthy individuals. The identification of OPG as a novel cardiovascular risk marker suggests an association between mediators of bone homeostasis and cardiovascular disease. Methods and Results-Serum levels of OPG and RANKL were analyzed in a prospective case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study, a cohort study of 25 663 men and women, where 951 apparently healthy individuals who developed a coronary event during 6 years' follow-up were matched by sex and age with 1705 healthy controls. Baseline OPG, but not RANKL, was higher in cases than in controls, and OPG was higher in women than in men. Both men and women in the highest OPG quartile had a higher risk for future CAD. These associations were independent of established cardiovascular risk factors, and when using OPG as a continuous variable, also after adjustment for CRP. In contrast, RANKL showed no association with coronary events. 
K ey regulators of bone formation are expressed in atherosclerotic plaques suggesting a link between mediators of bone metabolism and atherogenesis. 1,2 Particular attention has been drawn to osteoprotegerin (OPG), a soluble member of the tumor necrosis factor (TNF) receptor superfamily, which inhibits osteoclastogenesis by binding the receptor activator of nuclear factor-B ligand (RANKL), acting as a decoy receptor to inhibit RANKL interaction with its receptor, RANK. The OPG/RANKL/RANK axis has been shown to have pleiotropic effects on bone metabolism and the immune system, and recently this system has also been implicated in atherogenesis. Both OPG and RANKL can be detected in atherosclerotic lesions. 3 In humans, elevated circulating OPG concentrations have been associated with increased prevalence and severity of coronary artery disease (CAD), 4 ,5 cerebrovascular disease, 6 peripheral vascular disease, 7 and may also predict survival in patients with heart failure after acute myocardial infarction (MI). 8 However, epidemiological evidence about the relationship between OPG and risk of future CAD in the general population is limited to one population study with a limited number of incident CAD cases. 9 We hypothesized that among apparently healthy individuals, high serum concentrations of OPG and soluble RANKL could be associated with an increased risk of future CAD. We tested this hypothesis in the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) cohort. 10 
Methods
We performed a nested case-control study among participants of the EPIC-Norfolk study, a prospective population study of 25 663 men and women between 45 and 79 years, resident in Norfolk, UK, who completed a baseline questionnaire survey and attended a clinic visit, consisting of a health check and blood sampling. 10 EPIC-Norfolk is part of a 10-country collaborative EPIC-study and designed to investigate dietary and other determinants of cancer. Additional data were obtained to enable the assessment of determinants of other diseases.
Participants were recruited from age-sex registers of general practices. At the baseline visit between 1993 and 1997, participants answered a questionnaire with detailed information on health and lifestyle. Blood samples and additional data collection were performed as described earlier. 10 All participants have been registered for mortality at the UK Office of National Statistics, with vital status ascertained for the entire cohort. Death certificates were coded by trained nosologists according to International Classification of Disease (ICD) 9th revision. Death was considered attributable to CAD if the underlying cause was coded as 410 or 414, but unfortunately we have no data on the relative numbers of acute MI (code 410) and other forms of chronic ischemic heart disease (code 414). Participants admitted to a hospital were identified by their unique National Health Service number by data linkage with ENCORE (East Norfolk Health Authority database), which identifies all hospital contacts throughout England and Wales for Norfolk residents. Participants were identified as having CAD during follow-up if they had a hospital admission or died because of CAD. ICD coding for CAD was based on clinical diagnoses made by physicians, and this has previously been evaluated in a pilot validation study. 11 We report results with follow-up until January 2003 with a mean follow-up of 6.7Ϯ2.0 years. The Norwich District Health Authority Ethics Committee approved the study, and all participants gave signed informed consent.
Participants
We have previously reported similarly designed nested case-control studies, 11, 12 where 1138 cases were identified. Out of these, 19.7% suffered acute MI, 31.5% had unstable angina pectoris, 28.8% had chronic ischemic heart disease, and 20% had various combinations of these diagnoses. Furthermore, 5.6% had concomitant cerebrovascular disease, 8.3% had peripheral artery disease, and 3.1% had aortic stenosis. In the present nested case-control study, we identified 951 cases that had an incident coronary event (69.8%) or died of CAD (30.2%) during follow-up. All individuals reporting CAD or stroke at entry of the study or were on lipid reducing therapy were excluded. Control participants remained free of CAD during followup. We attempted to match 2 controls to each case from baseline clinic visit by sex, age (age of case plus or minus 2.5 years), and date of visit (within 3 months). There were 754 cases matched with 2 controls (79.3%) and 197 cases matched with 1 control (20.7%). The baseline data on previous diseases are based on the health questionnaire that was completed by every participant.
Biochemical Analysis
Lipid parameters were analyzed as described elsewhere. 12, 13 OPG and RANKL were measured in thawed serum and C-reactive protein (CRP) in citrated plasma (stored at Ϫ80°C). OPG and soluble RANKL were quantified by enzyme immunoassays (EIAs, R&D Systems; intra-and interassay coefficients of variation were Ͻ11% for both assays). 14 Plasma concentrations of CRP were measured as previously described. 15 Samples were analyzed in random order to avoid systemic bias. Researchers and laboratory personnel had no access to identifiable information and could identify samples by number only.
Statistical Analysis
Baseline characteristics were calculated for cases and controls. Data are presented as percentage (number) or meanϮSD where appropriate. OPG, sRANKL, triglycerides, and CRP levels had a skewed distribution and were therefore log-transformed before being used in statistical analyses, but in tables we present untransformed medians and corresponding interquartile ranges (IQR). Baseline characteristics were compared between cases and controls using mixed effect models for continuous variables and using conditional logistic regression for categorical variables. Mixed effect model tests the difference between the means of a continuous variable, between 2 groups that were matched to each other. We divided OPG levels into quartiles based on the distribution among controls. To evaluate the relationship between OPG and RANKL levels and other risk factors, we calculated mean levels of risk factors per OPG and RANKL quartile. To estimate the relative risk of future CAD, we calculated odds ratios (OR) and corresponding 95% confidence intervals (95%CI) per OPG quartile and a probability value for linearity across quartiles. ORs were calculated using conditional logistic regression, taking into account the matching for sex and age and enrollment time. ORs were calculated using regression models (1) without additional risk factors, (2) adjusting for smoking, diabetes, body mass index (BMI), LDL cholesterol, HDL cholesterol, and systolic blood pressure, and (3) adjusting for the risk factors in model 2 and in addition (log) CRP levels. The interaction term for OPG quartiles * sex was Pϭ0.7, and for RANKL quartiles * sex was Pϭ0.8, justifying the presentation of pooled data of men and women. However, sex-specific analyses were also performed using sexspecific quartile cut-offs. The lowest quartile was used as the reference category. A probability value Ͻ0.05 was considered to indicate statistical significance.
Results

Characteristics at Baseline
We identified 951 participants who did not report a history of CAD at baseline (those with lipid lowering therapy were also excluded), but developed CAD during follow-up. Of these, 668 (70.2%) experienced nonfatal and 283 (29.8%) fatal events. A total of 754 cases could be matched with 2 controls and 197 with 1 control, giving a control group consisting of 1705 individuals. Because of matching, age and sex were comparable between cases and controls ( Table 1) . As previously reported, 15 cases had higher BMI and were more likely to smoke, have diabetes, higher blood pressure, higher levels total cholesterol, LDL cholesterol, and triglycerides, and lower levels of HDL cholesterol than controls (Table 1) . CRP levels were higher in cases than controls, and higher in women than men (supplemental Table I , available online at http://atvb. ahajournals.org).
OPG and RANKL at Baseline
Baseline levels of OPG were higher in cases than in controls (Table 1) , and higher in women than in men in both cases and in controls (supplemental Table I ). In both sexes, age increased with increasing OPG quartiles (based on cases and controls; Table 2 and supplemental Table IIA) . Increasing quartiles of OPG were associated with higher blood pressure, but there was no association between OPG and BMI or smoking in either men or women. Diabetes was more prevalent in the higher OPG quartiles among men, but not among women. Whereas lipids were not associated with OPG levels in men, total cholesterol, LDL cholesterol, and triglycerides increased and HDL cholesterol decreased with increasing OPG levels in women. CRP increased with increasing OPG levels in men; though trends were similar in women, this association did not reach statistical significance.
Soluble RANKL levels were significantly associated with age, lipid parameters, BMI, and blood pressure in men, and with CRP in women (supplemental Table IIB ). However, there was no difference in serum levels of RANKL between cases and control or between sexes (Table 1 and supplemental  Table IIB ).
OPG and RANKL and Coronary Events
OPG quartiles showed a significant and linear association with the risk of future coronary events in both sexes (supple-mental Table III ) and when sexes were pooled (Table 3) . This association remained statistically significant after adjustment for the Framingham Risk Score, which incorporates traditional cardiovascular risk factors (ie, sex, age, diabetes, systolic blood pressure, smoking, total cholesterol, HDL cholesterol; Model 2), and when using OPG as a continuous variable, also on additional adjustment for logCRP in both sexes (Model 3). A similar pattern was observed when analyses were performed for fatal and nonfatal coronary events separately (data not shown). Although use of antihypertensive medication was more prevalent in cases than controls (Table 1) and although cases had a higher BMI, additional adjustment for these variables did not affect the observed associations. Although there was an unadjusted association between RANKL and future coronary events in men when using RANKL as a continuous variable, this association was lost when adjusting for other risk factors, and in contrast to OPG, we observed no significant association between RANKL quartiles and risk of future coronary events (Table 3) .
Discussion
In this large nested case-control study among apparently healthy individuals, an elevated serum level of OPG, but not RANKL, was associated with an increased risk of future coronary events. Both men and women in the highest OPG quartile had a significant higher risk for future CAD, compared to those in the lowest quartile. These associations were independent of established cardiovascular risk factors, and when using OPG as a continuous variable, also on adjustment for CRP. The magnitude of association is comparable to other risk factors for CAD such as CRP. [15] [16] [17] Recent epidemiological and clinical evidence from human studies suggest that the OPG/RANK/RANKL axis is linked to vascular disease. 18 The promoter region of the human OPG gene contains various binding sites, and some of these promoter polymorphisms were associated with vascular morphology and function in small-scale population studies. 19 Furthermore, elevated serum OPG levels have been associated with the progression of vascular calcification, 20 with the presence and severity of peripheral and coronary artery disease, 4, 7 with cardiovascular mortality in elderly women, 6 with aortic plaque in apparently healthy individuals, 21 and with long-term mortality after acute coronary syndromes. 22 Kiechl et al reported that OPG level could be associated with future cardiovascular events in the general population by examining 128 cases, including both coronary, cerebrovascular, and peripheral artery disease as well as aortic aneurism. 9 Herein we extend these findings by examining a much larger study population consisting of 951 cases, showing that OPG is associated with future coronary events, independent of traditional cardiovascular risk factors and CRP. The association of OPG with future cardiovascular events may have several explanations. First, serum OPG levels appear to be a stable and reliable marker not only of vascular calcification, but also of inflammation, potentially mirroring 2 interacting pathogenic processes in atherogenesis and plaque destabilization. Second, OPG expression has been demonstrated in both coronary smooth muscle cells, 23 endothelial cells, 24 and in vulnerable atherosclerotic lesions. 3, 25 It is therefore tempting to hypothesize that serum OPG levels reflect the extent of the atherosclerotic process. Finally, whereas OPG is thought to neutralize RANKL activity by inhibiting RANKL binding to RANK, OPG, at least at high concentrations, may enhance the matrix metalloproteinase (MMP)-inducing effect of RANKL as well as having MMPinducing and chemotactic effects of its own, 3, 26 suggesting a more direct role of OPG in the promotion of coronary events. Future studies should address whether OPG plays an active role in the development of CAD or is merely a marker.
In contrast to OPG, we found no or only minor association between coronary events and sRANKL even in univariate analyses, potentially reflecting that OPG is a more stable overall measure of RANKL/RANK activity than sRANKL. The ability of OPG to reflect RANKL/RANK activity, as a potential important mediator in atherogenesis and plaque destabilization, could contribute to its prognostic impact. In fact, the utility of serum parameters as risk predictors does not depend on their pathogenic importance, but rather on their ability to reflect important pathogenic processes. The present study may seem in conflict with a recent study by Kiechl et al, 27 showing the ability of sRANKL to predict cardiovascular events in apparently healthy individuals. The reason for this discrepancy is not clear, but similar to their OPG study from the same population, they examined a much lower number of cases (nϭ124), which also included patients with ischemic stroke and transient ischemic attack.
The prospective design, large sample size, long duration, completeness of follow-up, and high numbers of nonfatal and fatal events are all important strengths of the current study. However, the study also has some limitations. First, we identified CAD using hospital admission and mortality records. Exclusion of milder events not resulting in hospital admission may have underestimated absolute event rates and reduced the range of case severity. Second, kidney function could influence OPG levels, and unfortunately, we have no creatinine data on the study population. However, it is unlikely that this may be a major confounder in this large population of healthy individuals. Third, serum OPG was determined in a single sample that was obtained at a nonuniform time of the day. However, although Joseph et al reported circadian variation for OPG, they also showed that the OPG levels were stable between 0800 and 1500, 28 and importantly, all blood samples in the present study were taken in this period of the day. Fourth, we lack information of inflammatory disorders as well the use of bisphosphonates and steroids in the study population, which all potentially could influence our measurements. Fifth, there is no data on exact numbers of type 1 diabetes, but these numbers were low (Ͻ10%) and most likely, would not influence the results of our analysis. Finally, random measurement results in misclassification of cases and controls and therefore may be an underestimation of the true effect. 28 So we can conclude that the true effect may be even larger than we calculated. In addition, random measurement errors in both case ascertainment and exposure assessment would underestimate any relationships between OPG levels and CAD risk, and therefore do not negate our findings.
Elevated levels of OPG were associated with increased risk of future coronary events in this large prospective casecontrol study among apparently healthy men and women, independent of traditional cardiovascular risk factors. Our findings also suggest that OPG levels could be used for risk stratification for future coronary events in the general population. Data are mean ± SD, percentage (n), median (interquartile range) 
